THERAPY DOSSIER · th-06aa039138a4

Monophosphoryl lipid A

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00118625 ↗PHASE2completed

Contribution of MPL to tyrosine adsorbed birch, hazel and alder pollen allergoid (Tree MATA MPL)

Type I Hypersensitivity

Enrolment: 40 · Results not recorded

NCT00133146 ↗PHASE2completed

Contribution of MPL to tyrosine adsorbed grass and rye pollen allergoid

Type I Hypersensitivity

Enrolment: 41 · Results not recorded

NCT02038907 ↗PHASE2completed

Norovirus bivalent VLP vaccine adjuvanted with or without monophosphoryl lipid A and aluminium hydroxide

Healthy Volunteers · Norovirus Prevention

Enrolment: 420 · Results not recorded

NCT02142504 ↗PHASE2completed

Intramuscular norovirus GI.1/GII.4 bivalent VLP vaccine in healthy adults

Norovirus Prevention

Enrolment: 454 · Results not recorded

NCT01168401 ↗PHASE1completed

Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with monophosphoryl lipid A and aluminium hydroxide

Gastroenteritis

Enrolment: 102 · Results not recorded

NCT01717950 ↗PHASE1completed

CLASS-level surrogate: Na-APR-1 (M74)/Alhydrogel with glucopyranosyl lipid A aqueous formulation

Hookworm Infection

Enrolment: 40 · Results not recorded

NCT07111078 ↗PHASE1recruiting

CLASS-level surrogate: quadrivalent influenza HA stem vaccine with and without ALFQ (MPLA-containing) adjuvant

Influenza Prevention

Enrolment: 56 · Results not recorded

NCT01556945 ↗PHASE1|PHASE2completed

CLASS-level surrogate: FMP1 and RTS,S malaria vaccines adjuvanted with AS02 (MPL-containing)

Malaria, Falciparum

Enrolment: 72 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26538529 ↗2015Reported benefit

Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.

MouseBurnUnspecifiedBALB/cprophylactic treatment given after burn injury and before infection

Model: Burn injury followed by Pseudomonas aeruginosa burn wound infection and sepsis

Monophosphoryl lipid A mobilised neutrophils from bone marrow to blood and to the infection site, improved bacterial clearance and improved survival after burn wound infection, and all of these benefits were abolished by G-CSF neutralisation.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…